Ultimovacs ASA (OSL:ULTI) Short-Term Capital Lease Obligation : kr1.93 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Short-Term Capital Lease Obligation?

Ultimovacs ASA's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr1.93 Mil.

Ultimovacs ASA's quarterly Short-Term Capital Lease Obligation declined from Sep. 2023 (kr1.87 Mil) to Dec. 2023 (kr1.83 Mil) but then increased from Dec. 2023 (kr1.83 Mil) to Mar. 2024 (kr1.93 Mil).

Ultimovacs ASA's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (kr1.63 Mil) to Dec. 2022 (kr1.77 Mil) and increased from Dec. 2022 (kr1.77 Mil) to Dec. 2023 (kr1.83 Mil).

Ultimovacs ASA Short-Term Capital Lease Obligation Historical Data

The historical data trend for Ultimovacs ASA's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Short-Term Capital Lease Obligation Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.33

1.71

1.63

1.77

1.83

Ultimovacs ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.85	1.85	1.87	1.83	1.93

Ultimovacs ASA Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Ultimovacs ASA Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.